There is no definitive cure for MS. Immunomodulatory therapies, such as interferon-² (IFN-²) and glatiramer acetate (GA), are only partially effective. Hence, there is a pressing need both for novel therapeutic targets and for approaches toward increasing the effectiveness of these existing treatments.
The focus of the proposed United Europeans for the development of PHArmacogenomics in MS ( UEPHA-MS ) network will be to promote and improve training opportunities in the novel areas of pharmacogenomics, biomarker research and systems biology applied to MS. The main scientific goals of this network are both to improve our knowledge of the mechanisms determining response outcome of existing immunomodulatory therapies and to identify novel therapeutic opportunities. UEPHA-MS is composed of ten internationally recognised research teams from 6 countries with an assortment of expertise in complementary disciplines.
Source: CORDIS, http://cordis.europa.eu
Funding period: 15.09.2008 - 14.09.2012
Participant organisations: 9
Project funding: 2.360.000 Euro
Photomicrograph of a demyelinating MS-Lesion.
Klüver-Barrera-Stain. Orgininal Magnification 10x - Source: Wikimedia Commons